|11th August 2020||Eyal Rubin||246,146||Grant/award etc.||$0.00|
|11th August 2020||Dror Bashan||447,927||Grant/award etc.||$0.00|
|7th April 2020||Aharon Schwartz||64,000||Open or private purchase||$2.43||$155,264.00|
|9th March 2020||Aharon Schwartz||112,200||Sale back to the issuer||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins. It offers Taliglucerase alfa injections under the brand name Elelyso. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases.